Evidence map›Paper›PMID 41994018›Full record

ArticleESMO gastrointestinal oncology2026

D Ciardiello, L Boscolo Bielo, S Napolitano, E Martinelli, T Troiani, E Cioli, T P Latiano, E Maiello, P Parente, A Avallone and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

D CiardielloDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milano, Italy.
L Boscolo BieloDivision of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milano, Italy.
S NapolitanoDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
E MartinelliDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
T TroianiDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
E CioliDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milano, Italy.
T P LatianoMedical Oncology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
E MaielloMedical Oncology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
P ParentePathology Unit, Policlinico, Foggia, Italy.
A AvalloneExperimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy.
A De StefanoExperimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy.
R BordonaroMedical Oncology Unit, Azienda Ospedaliera ARNAS Garibaldi, Catania, Italy.
A E RussoMedical Oncology Unit, Azienda Ospedaliera ARNAS Garibaldi, Catania, Italy.
C LotesoriereMedical Oncology Unit, National Institute of Gastroenterology, IRCCS de Bellis Research Hospital, Castellana Grotte, Italy.
S VallarelliMedical Oncology Unit, National Institute of Gastroenterology, IRCCS de Bellis Research Hospital, Castellana Grotte, Italy.
S PiscontiMedical Oncology Unit, San Giuseppe Moscati Hospital, Statte, Italy.
C NisiMedical Oncology Unit, San Giuseppe Moscati Hospital, Statte, Italy.
E TamburiniDepartment of Oncology and Palliative Care, Cardinale G Panico, Tricase City Hospital, Tricase, Italy.
M G ViolaDepartment of Surgery, Cardinale G Panico, Tricase City Hospital, Tricase, Italy.
S LonardiDepartment of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
C CremoliniUnit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.
D IaconoMedical Oncology, Azienda Ospedaliera San Camillo Forlanini Roma, Rome, Italy.
P TagliaferriDepartment of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy.
F PietrantonioDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
G TortoraMedical Oncology, Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
G RosatiMedical Oncology Unit, "S. Carlo" Hospital, Potenza, Italy.
M G ZampinoDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milano, Italy.
G CuriglianoDivision of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milano, Italy.
A FebbraroMedical Oncology Unit, Casa di Cura Villa Maria - UPMC Hillman Cancer Center - Mirabella Eclano, Avellino, Italy.
N NormannoIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Mendola, Italy.
F De VitaDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
N FazioDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milano, Italy.
F CiardielloDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
G MartiniDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Human epidermal growth factor receptor 2 (HER-2) overexpression/amplification is a known prognostic and predictive biomarker in breast and gastric cancer. However, its role in metastatic colorectal cancer (mCRC) is still debated. Patients and methods: We conducted an exploratory analysis to investigate the role of Results: Patients with Conclusion: Taken together, these results highlight the need to test

Indexed as

anti-EGFRcetuximabCRCHER-2liquid biopsy

Identifiers

PMID41994018
PMCPMC13080806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.